Furthermore, CDNP-R848 treatment significantly decreased frequencies of anti-inflammatory Ly6C+/PD-L1+ myeloid-derived suppressor cells (MDSC) between tumor effector and clearing phases (Fig. 5c, f). The gene discussed is CD274; the disease is neoplasm.